OncoMatch/Clinical Trials/NCT06451497
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
Is NCT06451497 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies ZM008 for non small cell lung cancer.
Treatment: ZM008 — This is a phase 1 dose escalation trial of ZM008, an anti-LLT1 antibody as a single agent followed by combination with Pembrolizumab in patients with advanced solid tumors who have exhausted all standard therapy available or are intolerant of the same.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Small Cell Lung Carcinoma
Esophageal Carcinoma
Head and Neck Squamous Cell Carcinoma
Pancreatic Cancer
Cholangiocarcinoma
Prostate Cancer
Urothelial Carcinoma
Colorectal Cancer
Triple-Negative Breast Cancer
Breast Carcinoma
Diffuse Large B-Cell Lymphoma
Non-Hodgkin Lymphoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Lab requirements
Blood counts
Hemoglobin ≥9 g/dL (no transfusions in weeks); ANC ≥1.0 × 10^9/L (no growth factors in 2 previous weeks); Platelet count ≥75 × 10^9/L (no platelet transfusions in 2 previous weeks)
Kidney function
Estimated creatinine clearance (CrCL) ≥30 mL/minute (Cockcroft-Gault); if calculated CrCL <30 mL/min, measured CrCL ≥30 mL/min
Liver function
Total bilirubin ≤1.5 times ULN; AST and ALT ≤3.0 times ULN (≤5.0 times ULN if liver metastases present)
The patient has adequate hematologic function as defined by: Hemoglobin ≥9 g/dL... ANC ≥1.0 × 10^9/L... Platelet count ≥75 × 10^9/L... The patient has adequate hepatic function as defined by: Total bilirubin ≤1.5 times ULN. AST and ALT ≤3.0 times ULN, (if liver metastases are present, then ≤5.0 times ULN is allowed). The patient has adequate renal function as defined by: Estimated creatinine clearance (CrCL) using the Cockcroft-Gault formula ≥30 mL/minute. Patients with calculated CrCL <30 mL/minute can be enrolled if measured CrCL is ≥30 mL/minute.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Dana Farber Cancer Institute · Boston, Massachusetts
- NEXT Oncology · Austin, Texas
- NEXT Oncology · San Antonio, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06451497 currently recruiting?
Yes, this trial is currently recruiting patients.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify